Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

benmelstobart (APL-502)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Apollomics, JSR Life Sciences, Sino Biopharm

Drug class:

PD-L1 inhibitor

Related drugs:

‹

atezolizumab (236)

durvalumab (198)

sugemalimab (7)

envafolimab (6)

IO102-IO103 (4)

atezolizumab/hyaluronidase (1)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

›

EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
KRAS mutation	Biliary Tract Cancer	KRAS mutation	Biliary Tract Cancer	anlotinib + APL-502 Resistant: C3 – Early Trials anlotinib + APL-502 Resistant : C3	anlotinib + APL-502 Resistant: C3 – Early Trials anlotinib + APL-502 Resistant : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	APL-502 Resistant: C3 – Early Trials APL-502 Resistant : C3	APL-502 Resistant: C3 – Early Trials APL-502 Resistant : C3
TMB-H	Biliary Tract Cancer	TMB-H	Biliary Tract Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
EGFR wild-type + ALK wild-type + PD-L1 expression	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type + PD-L1 expression	Non Small Cell Lung Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
DNMT3A mutation	Triple Negative Breast Cancer	DNMT3A mutation	Triple Negative Breast Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
PIK3CA wild-type	Triple Negative Breast Cancer	PIK3CA wild-type	Triple Negative Breast Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
TMB-L	Triple Negative Breast Cancer	TMB-L	Triple Negative Breast Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3